Hematopoietic Stem Cell Mobilization
"Hematopoietic Stem Cell Mobilization" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
| Descriptor ID |
D019650
|
| MeSH Number(s) |
E02.095.410
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hematopoietic Stem Cell Mobilization".
Below are MeSH descriptors whose meaning is more specific than "Hematopoietic Stem Cell Mobilization".
This graph shows the total number of publications written about "Hematopoietic Stem Cell Mobilization" by people in this website by year, and whether "Hematopoietic Stem Cell Mobilization" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematopoietic Stem Cell Mobilization" by people in Profiles.
-
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019 03 26; 3(6):875-883.
-
Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018 12; 59(12):2829-2835.
-
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777.
-
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
-
A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Aug; 55(8):2010-6.
-
Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections. Transfusion. 2015 Aug; 55(8):2001-9.
-
Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant. 2015 Jan; 21(1):165-71.
-
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant. 2013 Jun; 48(6):777-81.
-
Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1867-75.